Literature DB >> 17428852

Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors.

Kimberly McCoy1, Nia Tatsis, Birgit Korioth-Schmitz, Marcio O Lasaro, Scott E Hensley, Shih-Wen Lin, Yan Li, Wynetta Giles-Davis, Ann Cun, Dongming Zhou, Zhiquan Xiang, Norman L Letvin, Hildegund C J Ertl.   

Abstract

In this study we compared a prime-boost regimen with two serologically distinct replication-defective adenovirus (Ad) vectors derived from chimpanzee serotypes C68 and C1 expressing Gag, Pol, gp140, and Nef of human immunodeficiency virus type 1 with a regimen in which replication-defective Ad vectors of the human serotype 5 (AdHu5) were given twice. Experiments were conducted in rhesus macaques that had or had not been preexposed to antigens of AdHu5. There was no significant difference in T-cell responses tested from peripheral blood of the different groups, although responses were overall highest in nonpreexposed animals immunized with the chimpanzee Ad vectors. Preexisting immunity to AdHu5 completely inhibited induction of transgene product-specific antibodies by the AdHu5 vectors without affecting antibody responses to the chimpanzee vectors. Upon euthanasia, T-cell responses were tested from a number of tissues. Preexisting immunity to AdHu5, commonly found in humans, changed the homing pattern of vaccine-induced T cells. In AdHu5-preexposed animals vaccinated with the chimpanzee Ad vectors, frequencies of transgene-specific T cells were higher in spleens than in blood, and in most preexposed animals vaccinated either with AdHu5 vectors or chimpanzee adenovirus vectors, frequencies of such T cells were exceptionally high in livers. The latter results indicate that analysis of T-cell responses solely from blood mononuclear cells of vaccine recipients may not suffice to compare the potencies of different vaccine regimens.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17428852      PMCID: PMC1900096          DOI: 10.1128/JVI.02497-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Renewed promise. Annual AIDS vaccine meeting highlights recent data from clinical trials and lessons on recruitment and retention of volunteers.

Authors:  Kristen Jill Kresge
Journal:  IAVI Rep       Date:  2005 Sep-Oct

2.  A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier.

Authors:  Z Q Xiang; Y Yang; J M Wilson; H C Ertl
Journal:  Virology       Date:  1996-05-01       Impact factor: 3.616

3.  High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects.

Authors:  Paul A Goepfert; Helen Horton; M Juliana McElrath; Sanjay Gurunathan; Guido Ferrari; Georgia D Tomaras; David C Montefiori; Mary Allen; Ya-Lin Chiu; Paul Spearman; Jonathan D Fuchs; Beryl A Koblin; William A Blattner; Sharon Frey; Michael C Keefer; Lindsey R Baden; Lawrence Corey
Journal:  J Infect Dis       Date:  2005-08-31       Impact factor: 5.226

Review 4.  Gene therapy: adenovirus vectors.

Authors:  K F Kozarsky; J M Wilson
Journal:  Curr Opin Genet Dev       Date:  1993-06       Impact factor: 5.578

5.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses.

Authors:  Y Yang; Q Li; H C Ertl; J M Wilson
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

6.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

Review 7.  Immunosuppression caused by measles virus: role of viral proteins.

Authors:  Yann M Kerdiles; Caroline I Sellin; Johan Druelle; Branka Horvat
Journal:  Rev Med Virol       Date:  2006 Jan-Feb       Impact factor: 6.989

8.  Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.

Authors:  Danilo R Casimiro; Ling Chen; Tong-Ming Fu; Robert K Evans; Michael J Caulfield; Mary-Ellen Davies; Aimin Tang; Minchun Chen; Lingyi Huang; Virginia Harris; Daniel C Freed; Keith A Wilson; Sheri Dubey; De-Min Zhu; Denise Nawrocki; Henryk Mach; Robert Troutman; Lynne Isopi; Donna Williams; William Hurni; Zheng Xu; Jeffrey G Smith; Su Wang; Xu Liu; Liming Guan; Romnie Long; Wendy Trigona; Gwendolyn J Heidecker; Helen C Perry; Natasha Persaud; Timothy J Toner; Qin Su; Xiaoping Liang; Rima Youil; Michael Chastain; Andrew J Bett; David B Volkin; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

9.  Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes.

Authors:  A Reyes-Sandoval; J C Fitzgerald; R Grant; S Roy; Z Q Xiang; Y Li; G P Gao; J M Wilson; H C J Ertl
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses.

Authors:  Y Yang; H C Ertl; J M Wilson
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

View more
  94 in total

1.  Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats.

Authors:  Jinying Ge; Xijun Wang; Lihong Tao; Zhiyuan Wen; Na Feng; Songtao Yang; Xianzhu Xia; Chinglai Yang; Hualan Chen; Zhigao Bu
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 2.  Cofactors that may influence vaccine responses.

Authors:  Guy de Bruyn
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

3.  Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.

Authors:  H Chen; Z Q Xiang; Y Li; R K Kurupati; B Jia; A Bian; D M Zhou; N Hutnick; S Yuan; C Gray; J Serwanga; B Auma; P Kaleebu; X Zhou; M R Betts; H C J Ertl
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

4.  A live attenuated Listeria monocytogenes vaccine vector expressing SIV Gag is safe and immunogenic in macaques and can be administered repeatedly.

Authors:  Gaia Sciaranghella; Samir K Lakhashe; Mila Ayash-Rashkovsky; Saied Mirshahidi; Nagadenahalli B Siddappa; Francis J Novembre; Vijayakumar Velu; Rama Rao Amara; Chenghui Zhou; Sufen Li; Zhongxia Li; Fred R Frankel; Ruth M Ruprecht
Journal:  Vaccine       Date:  2010-11-09       Impact factor: 3.641

5.  Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine.

Authors:  Sunil Kannanganat; Pragati Nigam; Vijayakumar Velu; Patricia L Earl; Lilin Lai; Lakshmi Chennareddi; Benton Lawson; Robert L Wilson; David C Montefiori; Pamela A Kozlowski; Bernard Moss; Harriet L Robinson; Rama Rao Amara
Journal:  J Immunol       Date:  2010-11-12       Impact factor: 5.422

6.  Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection.

Authors:  M Jeyanathan; N Thanthrige-Don; S Afkhami; R Lai; D Damjanovic; A Zganiacz; X Feng; X-D Yao; K L Rosenthal; M Fe Medina; J Gauldie; H C Ertl; Z Xing
Journal:  Mucosal Immunol       Date:  2015-04-15       Impact factor: 7.313

Review 7.  Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy.

Authors:  Takuya Osada; Michael A Morse; Amy Hobeika; H Kim Lyerly
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

8.  An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector.

Authors:  Dongming Zhou; Xiangyang Zhou; Ang Bian; Hua Li; Heng Chen; Juliana C Small; Yan Li; Wynetta Giles-Davis; Zhiquan Xiang; Hildegund C J Ertl
Journal:  Nat Protoc       Date:  2010-10-14       Impact factor: 13.491

9.  A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.

Authors:  Elizabeth S Gabitzsch; Younong Xu; Lois H Yoshida; Joseph Balint; Richard B Gayle; Andrea Amalfitano; Frank R Jones
Journal:  Immunol Lett       Date:  2008-12-13       Impact factor: 3.685

Review 10.  Progress and prospects: immune responses to viral vectors.

Authors:  S Nayak; R W Herzog
Journal:  Gene Ther       Date:  2009-11-12       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.